Please assess the completion status of the following clinical trial:

Trial Title: Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Müllerian carcinomas (primary epithelial ovarian, primary peritoneal, or fallopian tube) who have had a response to platinum-based chemotherapy and have a chemotherapy treatment-free interval of at least 6 months. These patients are designated potentially platinum-sensitive.~2. Measurable disease by radiological or clinical examination parameters.~3. No prior immunotherapy.~4. No concurrent steroids or radiation therapy.~5. Adequate hematological parameters (ANC \>/= 1500 cells/UL, platelets \>/= 100,000 cells/UL~6. Adequate renal function (serum creatinine \</= 1.5 mg/dl)~7. Adequate hepatic function (serum bilirubin \</= 1.5 mg/dl)~8. SGOT or SGPT \</= 2.5 normal~9. Zubrod status \</= 2~10. Signed informed consent~11. Patients with no more than 2 prior therapy regimens (1st line platinum and platinum reinduction will count as one)~Exclusion Criteria:~1. Pregnant or lactating women~2. Patients with brain metastases~3. Serum albumin \<3 gm/dl~4. Weight loss \>10% over 4 months~5. Radiation therapy to whole abdomen~6. History of clinical or EKG findings suggestive of active (within the last 6 months) heart disease~7. Patients with active autoimmune or inflammatory bowel disease~8. Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.~9. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.~10. Patients with prior hypersensitivity to platinum agents~11. Patients with history of other malignancy, with the exception of non-melanomatous skin cancer; unless in complete remission and off therapy for a minimum of 5 years.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemoimmunotherapy (Type: EXPERIMENTAL): GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).